Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2017

Aug 29, 2017

32418_dirs_2017-08-28_282bafe4-2bbe-437e-bb67-4e8d2c14f0c2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2017-08-25

Reporting Person: Allen Stephen R. (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-08-25 Common Stock P 2000 $3.31 Acquired 7000 Direct